drugset / Trial / NCT00402584

A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder

NCT00402584

Phase 3 Completed 304 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in subjects with binge-eating disorder.

Timeline

Start
2000-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sibutramine Small molecule 15 mg